CTOs on the Move

Beacon Orthopaedics & Sports Medicine

www.beaconortho.com

 
Beacon Orthopaedics has 40 renowned orthopedic surgeons providing Cincinnati, Dayton, NKY and Indiana specialized sports medicine and orthopedic care.
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million

Executives

Name Title Contact Details

Similar Companies

Acura Pharmaceuticals

Acura Pharmaceuticals is a Palatine, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cycle Pharmaceuticals

WHAT WE DO Cycle Pharmaceuticals is a global, privately-owned and patient-dedicated biotechnology company headquartered in Cambridge in the UK. Our mission is to utilise the latest pharmaceutical technologies to deliver superior drug treatments to b...

Accugenix

Accugenix offers a fixed pricing structure based upon turnaround time requirements. Whether your isolates are routine or require immediate attention, we have the operational flexibility and capacity to meet your needs. We also offer volume pricing

Cornerstone Family Healthcare

Cornerstone Family Healthcare is a comprehensive Hudson Valley medical care provider, offering urgent care, preventative care, womens health, pediatrics and more.

Akcea Therapeutics

Akcea Therapeutics is a development and commercialization company focused on helping patients with serious diseases. Our priority is to drive clinical program execution, understand patient and physician needs, prepare the market, create market access, and commercialize our products on a global basis. We are driven by knowing that patients depend on us. An affiliate of Ionis Pharmaceuticals and based in Kendall Square, Cambridge, Massachusetts, Akcea was founded with a robust portfolio of development-stage drugs covering multiple targets and disease states using advanced antisense therapeutics. Akcea is derived from the Greek word for value and worth. Something that has akcea (αξία) is not common, but precious and rare. Our name supports the value we are creating for physicians, patients and their families, and other key stakeholders as we seek to commercialize a robust portfolio of development-stage, advanced, antisense therapies for serious cardiometabolic lipid disorders. Our immediate focus is to drive our clinical programs forward through development to commercialization while building on the Isis standards of excellence.